Additionally, in a phase 2 clinical trial (NCT02639065) for patients with advanced esophageal and gastroesophageal junction adenocarcinoma, the use of the PD‐L1 inhibitor Durvalumab resulted in a heightened presence of anti‐inflammatory macrophages (Mamdani et al. 2021). This evidence concerns the gene CD274 and gastroesophageal junction adenocarcinoma.